Tesamorelin and Ipamorelin Together: What Has Actually Been Tested

Two compounds with very different records

A tesamorelin and ipamorelin blend is usually sold as a growth-hormone-axis combination: two compounds that both act upstream of growth hormone, bundled on the reasoning that two levers beat one.

The two halves are not equivalent, and the difference is the most useful thing on this page.

Tesamorelin is an approved drug. It is a growth-hormone-releasing factor analog approved for HIV-associated lipodystrophy, with a genuine phase 3 record behind that indication and 24 registered studies to its name. ¹ Read the detail on the tesamorelin page.

Ipamorelin is not approved for anything, and its registered record runs to three studies.

The approval does not travel

This is the trap the blend creates.

Tesamorelin's approval is for a specific product, at a specific indication, in a specific population — reduction of excess abdominal fat in people with HIV-associated lipodystrophy. It is not an approval for body composition in general, not an approval for anti-aging use, and emphatically not an approval that extends to a compounded mixture containing it.

A compounded blend of tesamorelin and something else is a different article from the approved product. It has not been through the review the approved product went through. Naming an approved drug as one ingredient does not make the mixture an approved drug, and it does not transfer the phase 3 evidence to the thing in the vial.

What happened when ipamorelin was actually tested

Ipamorelin's registered trials are the part of this story that marketing tends to leave out, because two of the three were run for a serious indication and did not succeed.

Ipamorelin was studied for post-operative ileus — the temporary shutdown of gut motility after abdominal surgery — on the reasoning that a ghrelin-receptor agonist should get the gut moving again. ² The program did not produce an approval. A compound with a plausible mechanism, a real clinical development effort behind it, and no approval at the end is not evidence of nothing; it is evidence that the effect was not big enough or reliable enough where it was measured.

That is a materially different picture from "ipamorelin is a growth hormone secretagogue", which is true and tells you nothing about whether it does anything useful in a person.

The combination

As of 14 August 2026, a search of ClinicalTrials.gov for "tesamorelin AND ipamorelin" returns zero registered studies.

Controls run in the same pass: "tesamorelin" returns 24, "ipamorelin" returns 3, "semaglutide" returns 763. The search works. There is nothing there for the pair.

So no one has published what happens when these two are given together — not the safety, not the interaction, not whether the combined effect on growth hormone is additive, redundant or self-limiting. Both compounds act on the same axis by different routes, which is precisely the situation where "more levers" and "the same lever twice" are hard to tell apart without measuring.

What growth hormone response is, and is not

Both compounds can raise growth hormone or IGF-1. That is a surrogate endpoint — a biological marker that moves, standing in for an outcome someone actually wants.

A marker moving is the beginning of a case, not the end of one. What a reader usually wants to know is whether body composition changes, whether injuries heal faster, whether anything gets better. Those are outcomes, they need to be measured directly, and for this combination they have not been.

The short version

One approved drug, at one indication, in one specific product. One unapproved compound whose most serious clinical test did not lead to an approval. Zero registered trials of the two together, checked 14 August 2026 with working controls.

The approval on the label of one ingredient is not evidence about the mixture, and that is the single thing most worth carrying away from this page.